surmount-1 tirzepatide non-diabetic obesity trial SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized, Tirzepatide once weekly for the

Legal analysts at Orrick described this as the FDA moving to shut the door on large-scale GLP-1 compounding

This isnt a new molecule its a strategic rebrand aimed at: Improving patient and provider awareness Reducing brand fragmentation across GLP1 therapies Simplifying prescribing, education, and prior authorization workflows As GLP1 utilization continues to grow, branding decisions like this have real implications for access, utilization management, and patient understanding.

Cagrilintide monotherapy data is more limited

The producer's website catalogs the products based on the people for whom they are intended